Кардиология: время генетики (по материалам конгресса «Генетика и сердце», 24–25 января 2020 года, Москва)
Кардиология: время генетики (по материалам конгресса «Генетика и сердце», 24–25 января 2020 года, Москва)
Соничева Н.А., Затейщиков Д.А. Кардиология: время генетики (по материалам конгресса «Генетика и сердце», 24–25 января 2020 года, Москва). Consilium Medicum. 2020 (22); 5: 35–39. DOI: 10.26442/20751753.2020.5.200185
________________________________________________
Sonicheva N.A., Zateyshchikov D.A. Cardiology: genetics’ time (by the materials of the “Genetics and Heart” Congress, January 24–25, 2020, Moscow). Consilium Medicum. 2020 (22); 5: 35–39. DOI: 10.26442/20751753.2020.5.200185
Кардиология: время генетики (по материалам конгресса «Генетика и сердце», 24–25 января 2020 года, Москва)
Соничева Н.А., Затейщиков Д.А. Кардиология: время генетики (по материалам конгресса «Генетика и сердце», 24–25 января 2020 года, Москва). Consilium Medicum. 2020 (22); 5: 35–39. DOI: 10.26442/20751753.2020.5.200185
________________________________________________
Sonicheva N.A., Zateyshchikov D.A. Cardiology: genetics’ time (by the materials of the “Genetics and Heart” Congress, January 24–25, 2020, Moscow). Consilium Medicum. 2020 (22); 5: 35–39. DOI: 10.26442/20751753.2020.5.200185
Наследственные кардиоваскулярные заболевания вносят весомый вклад в структуру сердечно-сосудистой патологии. Статья посвящена обзору материалов по генетически обусловленным кардиологическим заболеваниям, которые обсуждались на прошедшем в Москве Первом Международном конгрессе «Генетика и сердце». Приведены наиболее актуальные на сегодняшний день данные по гипертрофической и дилатационной кардиомиопатиям, наследственным проблемам аритмогенеза. Перечислены основные участники конгресса.
Hereditary cardiovascular diseases are of great importance in the structure of cardiovascular disease. The article provides a review of materials on genetically mediated heart diseases, which were discussed at the "Genetics and Heart" First International Congress (Moscow). The most relevant current date on hypertrophic and dilated cardiomyopathies as well as hereditary issues of arrhythmogenesis are presented. The main participants of the congress are listed.
1. Charron P, Arad M, Monserrat L et al. Genetic counselling and testing in cardiomyopathies: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2010; 31 (22): 2715–28.
2. Ackerman М et al. HRS/EHRA Expert Consensus Statement on Genetic Testing. Heart Rhythm 2011; 8 (8).
3. Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35 (39): 2733–79.
4. Jan Haas et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 2015; 36: 1123–35.
5. Priori SG et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2015; 8 (9): 746–837.
6. Manonelles P et al. Estudio de la muertesúbita en deportistas españoles. Investig Cardiovasc 2006; 9 (1): 55–73.
7. Hayashi M et al. The spectrum of epidemiology underlying sudden cardiac death. Circ Res 2015; 116: 1887–906.
8. Monserrat L. Perspectives on current recommendations for genetic testing in HCM. GCSP 2018; 23.
9. Cerrone M, Priori SG. Genetics of sudden death: focus on inherited channelopathies. Eur Heart J 2011; 32: 2109–18. DOI: 10.1093/eurheartj/ehr082
10. Bezzina CR, Lahrouchi N, Priori SG. Genetics of Sudden Cardiac Death. Circulation 2015; 116: 1919–36. DOI: 10.1161/CIRCRESAHA.116.304030
11. Charron P, Carrier L, Dubourg O et al. Penetrance of familial hypertrophic cardiomyopathy. Genet Couns 1997; 8: 107–14.
12. Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm 2012; 9: 57–63. DOI:10.1016/j.hrthm.2011.08.009
13. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270–6. DOI:10.1093/eurheartj/ehm342
14. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013; 381: 242–55. DOI: 10.1016/S0140-6736(12)60397-3
15. Garcia-Giustiniani D et al. Phenotype and prognostic correlations of the converter region mutations affecting the b myosin heavy chain. Heart 2015; 101: 1047–53.
16. Rapezzi C et al. Diagnostic work-up in cardiomyopathies: Bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34 (19): 1448–58.
17. Харлап М.С., Мясников Р.П., Павлунина Т.О. и др. Кардиологический фенотип болезни Фабри. Рос. кардиол. журн. 2018; 23 (7): 80–3.
[Kharlap M.S., Miasnikov R.P., Pavlunina T.O. et al. Kardiologicheskii fenotip bolezni Fabri. Ros. kardiol. zhurn. 2018; 23 (7): 80–3 (in Russian).]
18. Falk RJ et al. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol 2016; 68: 1323–41.
19. Ochoa JP et al. Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. JAAC 2018; 72 (20).
20. Ochoa JP et al. Deletions of specific exons of FHOD3 detected by next-generation-sequencing are associated with hypertrophic cardiomyopathy. Clin Genetics 2020.
21. MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy News relies.
22. Pelliccia A, Maron BJ, Culasso F et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000; 102: 278–84.
23. Batzner A et al. Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol 2018; 72: 3087–94.
24. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet 2010; 375: 752–62. DOI: 10.1016/S0140-6736(09)62023-7
25. Fernández X et al. Sudden Death in a Patient With Lamin A/C Gene Mutation and Near Normal Left Ventricular Systolic Function. Int J Cardiol 2008.
26. Ortiz Genga MF et al. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. J Am Coll Cardiol 2016; 68 (22).
27. López-Ayala JM et al. Desmoplakin truncation and ALVC: characterizing a phenotype. Europace 2014.
28. Гордеева М.В. и др. Аритмогенная кардиомиопатия/дисплазия правого желудочка как причина внезапной сердечной смерти молодых людей. Вестн. аритмологии. 2012; 69.
[Gordeeva M.V. et al. Aritmogennaia kardiomiopatiia/displaziia pravogo zheludochka kak prichina vnezapnoi serdechnoi smerti molodykh liudei. Vestn. aritmologii. 2012; 69 (in Russian).]
29. Fedyakov MA, Veleslavova OE, Romanova OV et al. New frameshift mutation found in PKP2 gene in arhythmogenic right ventricular cardiomyopathy/dysplasia: a family case study. Vestnik of Saint Petersburg University 2019; 14.
30. Arbustini et al. Human "Nuclear" Mitochondrial Cardiomyopathy a Novel Mouse Model Characterizes the Disease. JACC 2011.
31. Priori SG et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348 (19): 1866–74.
32. Mazzanti A et al. Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. J Am Coll Cardiol 2018; 71 (15): 1663–71.
33. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society/ J Am Coll Cardiol. 2018 Oct 2;72(14):e91-e220.
34. Соничева Н.А. Генетика и внезапная сердечная смерть. В кн.: Руководство по аритмологии. 2019.
[Sonicheva N.A. Genetika i vnezapnaia serdechnaia smert'. V kn.: Rukovodstvo po aritmologii. 2019 (in Russian).]
35. WHO. Innovative Care for Chronic Conditions: Building Blocks for Action. 2002.
36. Воинова В.Ю., Школьникова М.А., Найговзина Н.Б. Ресурсы оказания медицинской помощи больным с орфанными заболеваниями в различных странах. Доктор.Ру. 2018; 4 (148): 6–13.
[Voinova V.Iu., Shkol'nikova M.A., Naigovzina N.B. Resursy okazaniia meditsinskoi pomoshchi bol'nym s orfannymi zabolevaniiami v razlichnykh stranakh. Doktor.Ru. 2018; 4 (148): 6–13 (in Russian).]
________________________________________________
1. Charron P, Arad M, Monserrat L et al. Genetic counselling and testing in cardiomyopathies: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2010; 31 (22): 2715–28.
2. Ackerman М et al. HRS/EHRA Expert Consensus Statement on Genetic Testing. Heart Rhythm 2011; 8 (8).
3. Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35 (39): 2733–79.
4. Jan Haas et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 2015; 36: 1123–35.
5. Priori SG et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2015; 8 (9): 746–837.
6. Manonelles P et al. Estudio de la muertesúbita en deportistas españoles. Investig Cardiovasc 2006;
9 (1): 55–73.
7. Hayashi M et al. The spectrum of epidemiology underlying sudden cardiac death. Circ Res 2015; 116: 1887–906.
8. Monserrat L. Perspectives on current recommendations for genetic testing in HCM. GCSP 2018; 23.
9. Cerrone M, Priori SG. Genetics of sudden death: focus on inherited channelopathies. Eur Heart J 2011; 32: 2109–18. DOI: 10.1093/eurheartj/ehr082
10. Bezzina CR, Lahrouchi N, Priori SG. Genetics of Sudden Cardiac Death. Circulation 2015; 116: 1919–36. DOI: 10.1161/CIRCRESAHA.116.304030
11. Charron P, Carrier L, Dubourg O et al. Penetrance of familial hypertrophic cardiomyopathy. Genet Couns 1997; 8: 107–14.
12. Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm 2012; 9: 57–63. DOI: 10.1016/j.hrthm.2011.08.009
13. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270–6. DOI: 10.1093/eurheartj/ehm342
14. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013; 381: 242–55. DOI: 10.1016/S0140-6736(12)60397-3
15. Garcia-Giustiniani D et al. Phenotype and prognostic correlations of the converter region mutations affecting the b myosin heavy chain. Heart 2015; 101: 1047–53.
16. Rapezzi C et al. Diagnostic work-up in cardiomyopathies: Bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34 (19): 1448–58.
17. Kharlap M.S., Miasnikov R.P., Pavlunina T.O. et al. Kardiologicheskii fenotip bolezni Fabri. Ros. kardiol. zhurn. 2018; 23 (7): 80–3 (in Russian).
18. Falk RJ et al. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol 2016; 68: 1323–41.
19. Ochoa JP et al. Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. JAAC 2018; 72 (20).
20. Ochoa JP et al. Deletions of specific exons of FHOD3 detected by next-generation-sequencing are associated with hypertrophic cardiomyopathy. Clin Genetics 2020.
21. MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy News relies.
22. Pelliccia A, Maron BJ, Culasso F et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000; 102: 278–84.
23. Batzner A et al. Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol 2018; 72: 3087–94.
24. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet 2010; 375: 752–62. DOI: 10.1016/S0140-6736(09)62023-7
25. Fernández X et al. Sudden Death in a Patient With Lamin A/C Gene Mutation and Near Normal Left Ventricular Systolic Function. Int J Cardiol 2008.
26. Ortiz Genga MF et al. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. J Am Coll Cardiol 2016; 68 (22).
27. López-Ayala JM et al. Desmoplakin truncation and ALVC: characterizing a phenotype. Europace 2014.
28. Gordeeva M.V. et al. Aritmogennaia kardiomiopatiia/displaziia pravogo zheludochka kak prichina vnezapnoi serdechnoi smerti molodykh liudei. Vestn. aritmologii. 2012; 69 (in Russian).
29. Fedyakov MA, Veleslavova OE, Romanova OV et al. New frameshift mutation found in PKP2 gene in arhythmogenic right ventricular cardiomyopathy/dysplasia: a family case study. Vestnik of Saint Petersburg University 2019; 14.
30. Arbustini et al. Human "Nuclear" Mitochondrial Cardiomyopathy a Novel Mouse Model Characterizes the Disease. JACC 2011.
31. Priori SG et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348 (19): 1866–74.
32. Mazzanti A et al. Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. J Am Coll Cardiol 2018; 71 (15): 1663–71.
33. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society/ J Am Coll Cardiol. 2018 Oct 2;72(14):e91-e220.
34. Sonicheva N.A. Genetika i vnezapnaia serdechnaia smert'. V kn.: Rukovodstvo po aritmologii. 2019 (in Russian).
35. WHO. Innovative Care for Chronic Conditions: Building Blocks for Action. 2002.
36. Voinova V.Iu., Shkol'nikova M.A., Naigovzina N.B. Resursy okazaniia meditsinskoi pomoshchi bol'nym s orfannymi zabolevaniiami v razlichnykh stranakh. Doktor.Ru. 2018; 4 (148): 6–13 (in Russian).
Авторы
Н.А. Соничева*1, Д.А. Затейщиков2,3
1 Международная генетическая лаборатория Health in Code, Ла Корунья, Испания;
2 ГБУЗ «Городская клиническая больница №51» Департамента здравоохранения г. Москвы, Москва, Россия;
3 ФГБОУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ, Москва, Россия
*natalia.sonicheva@healthincode.com
________________________________________________
Natalia A. Sonicheva*1, Dmitry A. Zateyshchikov2,3
1 Health in Code, La Coruña, Spain;
2 City Clinical Hospital №51, Moscow, Russia;
3 Central State Medical Academy, Moscow, Russia
*natalia.sonicheva@healthincode.com